Thelansis

Progressive Pulmonary Fibrosis (PPF) Market Outlook Thelansis’s “Progressive Pulmonary Fibrosis (PPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Pulmonary Fibrosis (PPF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

  Progressive Pulmonary Fibrosis (PPF) Market Outlook Thelansis’s “Progressive Pulmonary Fibrosis (PPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Pulmonary Fibrosis (PPF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Progressive Pulmonary Fibrosis (PPF) Overview Progressive pulmonary fibrosis (PPF) is a lung disease that gets worse over time. It is caused by scarring of the lungs, which makes it harder to breathe. PPF can occur in people with any interstitial lung disease (ILD). However, it is more common in people with certain types of ILD, such as idiopathic non-specific interstitial pneumonia (iNSIP), con...

  Progressive pulmonary fibrosis (PPF) is a lung disease that gets worse over time. It is caused by scarring of the lungs, which makes it harder to breathe. PPF can occur in people with any interstitial lung disease (ILD). However, it is more common in people with certain types of ILD, such as idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease-related ILD (CTD-ILD), and fibrotic hypersensitivity pneumonitis. PPF is more likely to occur in older people who have smoked cigarettes, have bronchiectasis (widening of the airways), have a certain pattern of scarring on their lungs on a high-resolution computed tomography (HRCT) scan, have not had their disease improve, or stabilize, have short telomere syndrome, are Black American, or have gastroesophageal reflux disease (GERD). Certain biomarkers can be measured in the blood to help identify people who are at risk of developing PPF. These biomarkers include the MUCB promoter gene, KL-6, CCL-16, matrix met...